Tyra Biosciences, Inc. (TYRA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $20.43. The rating moved from Neutral to Oversold on October 2, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$20.43
• Last changeMoved from Neutral to Oversold on October 2, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Tyra Biosciences, Inc. (TYRA) is a clinical‑stage biotech whose valuation will be highly sensitive to upcoming clinical and corporate catalysts. Recent market tone is cautious and volumes light, which raises the bar for positive news to move the stock materially. Investor appetite for conviction biotech can support upside on favorable trial or partnership news, but lack of recent filing details and broad payer/pricing headwinds increase downside and dilution risk. Near term, watch upcoming clinical milestones, cash runway disclosures, and any business development activity; absent clear positive catalysts, expect range‑bound trading with elevated volatility.

Key factors

• Clinical‑stage pipeline with potential near‑term catalysts (trial readouts, IND updates or partnerships) that can re‑rate the equity if positive
• Specialty biotech investor appetite for select late‑stage and conviction names provides episodic valuation support for clinical successes
• Macro risk‑off environment and light volumes limit near‑term upside absent a clear catalyst; biotech stocks often gap with clinical news
• Policy and payer focus on drug affordability (Medicare negotiation/IRA) increases pricing and access uncertainty for novel therapies
• Limited public visibility on recent filings or updated financials in the provided dataset increases uncertainty around cash runway and dilution risk

Risks

• Binary clinical trial outcomes or regulatory setbacks that could cause significant share price declines
• Funding and dilution risk if cash runway is insufficient or capital markets remain constrained during risk‑off periods
• Downward pricing pressure and reimbursement constraints driven by Medicare negotiation and payer cost containment
• Sector‑wide volatility from macro events (rate speculation, geopolitical headlines) that compresses small‑cap biotech valuations
• Competition from larger, better‑funded pharmaceutical players or alternative therapeutic approaches

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.